These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9352145)

  • 1. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome.
    Stasi R; Brunetti M; Bussa S; Conforti M; Martin LS; La Presa M; Bianchi M; Parma A; Pagano A
    Clin Lab Haematol; 1997 Sep; 19(3):197-201. PubMed ID: 9352145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin.
    Musto P; Matera R; Minervini MM; Checchia-de Ambrosio C; Bodenizza C; Falcone A; Carotenuto M
    Haematologica; 1994; 79(3):265-8. PubMed ID: 7926977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to recombinant human erythropoietin in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Bussa S; Conforti M; Di Giulio C; Crescenzi A; Terzoli E; Vecchione A; Pagano A
    Clin Cancer Res; 1997 May; 3(5):733-9. PubMed ID: 9815743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes.
    Alexandrakis M; Coulocheri S; Xylouri I; Ganotakis E; Eliakis P; Karkavitsas N; Eliopoulos GD
    Haematologia (Budap); 1998; 29(1):13-24. PubMed ID: 9704253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
    Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
    J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of serum cytokine levels in patients with myelodysplastic syndromes.
    Verhoef GE; De Schouwer P; Ceuppens JL; Van Damme J; Goossens W; Boogaerts MA
    Leukemia; 1992 Dec; 6(12):1268-72. PubMed ID: 1280751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of tumor necrosis factor-alpha and interferon-gamma on erythropoietin production and erythropoiesis in cancer patients with anemia].
    Wang W; Zhang MH; Yu Y; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):681-4. PubMed ID: 18399174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
    Marques da Costa R
    Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of serum levels of macrophage colony-stimulating factor (M-CSF) in patients with uremia.
    Kawano Y; Takaue Y; Motoyoshi K; Minakuchi J; Kawashima S; Saito S; Hirao A; Sato J; Shimizu T; Kuroda Y
    Exp Hematol; 1993 Feb; 21(2):220-3. PubMed ID: 8425560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of human recombinant erythropoietin on inflammatory status in peritoneal dialysis patients.
    Aguilera A; Bajo MA; Díez JJ; Ruiz-Caravaca ML; Vicenta Cuesta M; Alvarez V; Codoceo R; Selgas R
    Adv Perit Dial; 2002; 18():200-5. PubMed ID: 12402619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes.
    Stenke L; Wallvik J; Celsing F; Hast R
    Leukemia; 1993 Sep; 7(9):1324-7. PubMed ID: 8371582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
    Stasi R; Pagano A; Terzoli E; Amadori S
    Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature.
    Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Torrebadell M; Montserrat E
    Br J Haematol; 2004 Nov; 127(4):399-403. PubMed ID: 15521916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
    Azzarà A; Carulli G; Galimberti S; Baratè C; Fazzi R; Cervetti G; Petrini M
    Am J Hematol; 2011 Sep; 86(9):762-7. PubMed ID: 21850658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
    Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
    Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.